Table 1.

Characteristics of Individuals in the Matched Sample by Vaccination Status

Characteristic	Vaccinated (n = 5660)		Unvaccinated (n = 5660)
	n	%	n	%
Age group, y
18–29	964	17.0	1003	17.7
30–39	2622	46.4	2607	46.1
40–49	1557	27.5	1534	27.1
≥50	517	9.1	516	9.1
Childhood smallpox vaccination
Yes	1	0.0	1	0.0
No	44	0.8	48	0.8
Unknown	5615	99.2	5611	99.2
Autonomous region
Andalusia	926	16.4	926	16.4
Asturias	37	0.7	37	0.7
Balearic Islands	361	6.4	361	6.4
Canary Islands	212	3.7	212	3.7
Castile and León	59	1.0	59	1.0
Castilla-La Mancha	59	1.0	59	1.0
Catalonia	2121	37.5	2121	37.5
Valencian Community	351	6.2	351	6.2
Extremadura	27	0.5	27	0.5
Galicia	252	4.5	252	4.5
Community of Madrid	830	14.7	830	14.7
Region of Murcia	129	2.3	129	2.3
Navarre	44	0.8	44	0.8
Basque Country	293	5.2	293	5.2
La Rioja	2	0.0	2	0.0
Mpox virus infection
Yes	18	0.3	25	0.4
No	5642	99.7	5635	99.6
Mpox symptomsa
Yes	18	100.0	25	100.0
No	0	0.0	0	0.0
Hospitalizationa
Yes	0	0.0	0	0.0
No	18	100.0	25	100.0
Admitted to intensive care unita
Yes	0	0.0	0	0.0
No	18	100.0	25	100.0
Deatha
Yes	0	0.0	0	0.0
No	18	100.0	25	100.0
MVA-BN product
IMVANEX	340	6.0	-	-
JYNNEOS	3554	62.8	-	-
Unknown	1766	31.2	-	-
MVA-BN route of administration
Intradermal (0.1 mL)	3502	61.9	-	-
Subcutaneous (0.5 mL)	1707	30.2	-	-
Unknown	451	7.9	-	-

Abbreviation: MVA-BN, modified vaccinia Ankara-Bavaria Nordic.

^aProportion is estimated with the total (100%) being the number of mpox virus infections.